Jonathan Smith, Author at Labiotech.eu

About

Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here!
Out of the office, I travel, play video games and board games, drink beer and play the piano.

Articles by Jonathan Smith

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront and developmental milestone payments, as well as up to €100M in undisclosed commercial milestone payments. AMAL’s vaccine development pipeline includes five preclinical programs. The lead […]

July 16, 2019 - 2 minutesmins - By Jonathan Smith

graphene bacteria rochester delft university

News and Trends 15 Jul 2019

Dutch-US Scientists Use Bacteria to Produce Graphene for Electronics

An international group of researchers has made graphene more affordably and with a lower environmental impact than current chemical methods by using bacteria. Graphene is a very strong and conductive material that could revolutionize electronics and engineering. However, producing graphene in large quantities requires lots of energy and involves toxic chemicals, such as hydrazine, which […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

omics aromics barcelona panorama mesothelioma

Startup Scout 12 Jul 2019

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Next time you travel to Barcelona, Spain, check out Aromics, a biotech that is using genomics and proteomics to develop treatments for cancers such as malignant mesothelioma, which can be caused by asbestos. Mission: To use omics technology to treat drug-resistant cancers, as well as to identify cancer biomarkers that could improve monitoring in clinical […]

July 12, 2019 - 3 minutesmins - By Jonathan Smith

bayer bacteriophage ecophage agriculture

More News! 11 Jul 2019

Bayer Launches Israeli Company to Develop Viruses Against Crop Disease

Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […]

July 11, 2019 - 2 minutesmins - By Jonathan Smith

microphyt microalgae obesity cognitive decline

More News! 11 Jul 2019

French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae

The French biotech Microphyt has raised €28.5M ($32M) to commercialize nutritional and cosmetic products harvested from microalgae. Over the next 18 months, Microphyt will use the money to ramp up its workforce and industrial capacity in preparation for pushing its microalgal food ingredients and cosmetics to market. The company is developing technology to overcome a […]

July 11, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Jul 2019

French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A

The French biotech Osivax has advanced in the race to develop a universal flu vaccine, raising €8M to achieve clinical proof-of-concept. Osivax will use most of the funding to progress its lead candidate vaccine towards market approval. Targeting all strains of influenza A viruses, the vaccine is currently in a phase I trial, with results […]

July 10, 2019 - 2 minutesmins - By Jonathan Smith

anti aging cardiovascular disease centenarian gene therapy

News and Trends 10 Jul 2019

Anti-Aging Gene Therapy Treats Cardiovascular Disease in Mice

A research group in Italy has reduced cardiovascular disease in mice by expressing an anti-aging gene often seen in centenarians. This could one day lead to a gene therapy treating the same condition in humans. Centenarians have long lives thanks to a mix of their environment, lifestyle, and their genes. In the past, researchers at […]

July 10, 2019 - 3 minutesmins - By Jonathan Smith

adc therapeutics antibody drug conjugates

News and Trends 9 Jul 2019

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jul 2019

European Biotech: The Insider View

How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […]

July 7, 2019 - 10 minutesmins - By Jonathan Smith

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Jonathan Smith

About

Articles by Jonathan Smith

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

Dutch-US Scientists Use Bacteria to Produce Graphene for Electronics

Gilead Pays Billions for Access to Galapagos’ Pipeline

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Bayer Launches Israeli Company to Develop Viruses Against Crop Disease

French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae

French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A

Anti-Aging Gene Therapy Treats Cardiovascular Disease in Mice

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

European Biotech: The Insider View

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Jonathan Smith

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!